 
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61   1 
 2 Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes with AID Use  
  Study Sponsor: Tandem Diabetes Care, Inc. [ADDRESS_785514] 
San Diego, CA [ZIP_CODE]  Study Number:  TP-0009348  Study Phase:  Feasibility  IDE Number:  G210262  Study Device: 1) t:slim X2 Insulin Pump with Control-IQ 1.0 technology 2) Settings initializer and adaptation algorithm   Protocol Chair: Jordan Pi[INVESTIGATOR_3388], MD  Date: [ADDRESS_785515] 2021  Version:  2.0  3 
Confidentiality Statement  4 
==================================================================================  5 
The information contained herein is confidential information that is the sole and exclusive 6 
property of Tandem Diabetes Care, Inc. and may not be divulged to any person (exc ept as 7 
required by [CONTACT_2371]) without the prior written consent of Tandem Diabetes Care, Inc. No part of it 8 
may be transmitted, reproduced, published, or used by [CONTACT_595060] 9 
permission. 10 
  11 
Page B2
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785516] Version Approved by [CONTACT_8415] 13 
Page B3
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785517] POPULATION  ................................................................................................ .........................................  17 27 
6.1.1 Inclusion Criteria:  ................................................................................................ ................................ . 17 28 
6.1.2 Exclusion Criteria: ................................................................................................ ................................ . [ADDRESS_785518] WITHDRAWAL OR TERMINATION  ...............................................................................................................  18 30 
7 TREATMENT OF SUBJECTS  ...........................................................................................................................  19 31 
7.1 THE T:SLIM X2 INSULIN PUMP WITH CONTROL -IQ TECHNOLOGY  ..................................................................................  19 32 
7.2 ENROLLMENT PROCEDURE : ................................................................................................ ...................................  19 33 
7.3 DURATION OF THERAPY AND FOLLOW -UP: ...............................................................................................................  19 34 
7.4 STUDY PROCEDURES :................................................................................................ ...........................................  19 35 
7.5 EARLY TERMINATION VISIT (IF APPLICABLE ) .............................................................................................................  [ADDRESS_785519] STUDY PHONE CALL ................................................................................................ ....................................  23 39 
8 STATISTICAL CONSIDERATIONS  ...................................................................................................................  24 40 
8.1 STATISTICAL ANALYSIS : ................................................................................................ ........................................  24 41 
9 RISKS AND BENEFITS ................................................................................................ ....................................  25 42 
9.1 POTENTIAL RISKS AND BENEFITS OF THE DEVICE  .......................................................................................................  25 43 
9.2 VENIPUNCTURE RISKS ................................................................................................ .........................................  25 44 
9.3 FINGERSTICK RISKS ................................................................................................ .............................................  25 45 
9.4 SUBCUTAN EOUS CATHETER RISKS (CGM)  ...............................................................................................................  25 46 
9.5 RISK OF HYPOGLYCEMIA  ................................................................................................ ......................................  25 47 
9.6 RISK OF HYPERGLYCEMIA  ................................................................................................ .....................................  26 48 
9.7 RISK OF DEVICE REUSE ................................................................................................ ........................................  26 49 
9.8 OTHER RISKS ................................................................................................ .....................................................  26 50 
9.9 KNOWN POTENTIAL BENEFITS  ...............................................................................................................................  26 51 
9.10 RISK ASSESSMENT  ................................................................................................ ..........................................  26 52 
9.11 GENERAL CONSIDERATIONS  .............................................................................................................................  27 53 
10 DESCRIPTION OF THE STUDY DEVICES AND USE  ..........................................................................................  28 54 Page B4
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  10.1 INSULIN PUMP ................................................................................................ ..............................................  28 55 
10.2 CONTINUOUS GLUCOSE MONITORING  ...............................................................................................................  28 56 
10.3 BLOOD GLUCOSE METER AND STRIPS  ................................................................................................................  28 57 
10.4 KETONE METER AND STRIPS  ............................................................................................................................  28 58 
10.5 STUDY DEVICE ACCOUNTABILITY PROCEDURES  ....................................................................................................  28 59 
10.6 BLOOD GLUCOSE METER TESTING  ....................................................................................................................  28 60 
10.7 BLOOD KETONE TESTING  ................................................................................................ ................................ . 29 61 
10.8 CGM  CALIBRATION  ................................................................................................ .......................................  29 62 
10.9 HYPERGLYCEMIA SAFETY PROTOCOL  ..................................................................................................................  29 63 
10.10  HYPOGLYCEMIA SAFETY PROTOCOL  ...................................................................................................................  29 64 
11 ADVERSE EVENTS, DEVICE ISSUES, AND STOPPI[INVESTIGATOR_16442]  ...........................................................................  30 65 
11.1 ADVERSE EVENTS ................................................................................................ ...........................................  30 66 
11.2 REPORTABLE ADVERSE EVENTS  .........................................................................................................................  31 67 
11.3 HYPOGLYCEMIC EVENTS  ................................................................................................ ..................................  31 68 
11.4 HYPERGLYCEMIC EVENTS /DIABETIC KETOACIDOSIS ...............................................................................................  [ADDRESS_785520]  ................................................................................................ .......................................  38 89 
13.5 INSTITU TIONAL REVIEW BOARDS  ......................................................................................................................  38 90 
13.6 CONSENT PROCEDURES AND DOCUMENTATION  ...................................................................................................  39 91 
13.7 PARTICIPANT AND DATA CONFIDENTIALITY  .........................................................................................................  39 92 
13.8 PARTICIPANT WITHDRAWAL  ............................................................................................................................  40 93 
13.9 CONFIDENTIALITY  ................................................................................................ ..........................................  40 94 
14 REFERENCES  ................................................................................................ ................................................  41 95 
 96 
  97 
Page B5
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  1 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_418069] 98 
COMPLIANCE 99 
Protocol Identifying Number: TP-0009348 
Protocol Name:  [CONTACT_595081] / Date : 2.0 / [ADDRESS_785521] 2021 
 100 
The Principal Investigators (undersigned) hereby [CONTACT_595061] [ADDRESS_785522] access to all 107 
documentation, including source data, by [CONTACT_595062] 108 
Care, Inc., IRBs and/or by [CONTACT_66695], State and local reg ulatory authorities.  109 
 110 
Investigator Name:  ___________________________________________ 111 
 112 
Investigator Signature:  ________________________________________ 113 
 114 
Date (DD/MMM/YYYY):  ______________________________________ 115 
  116 
Page B6
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785523] AE Adverse Event CGM Continuous Glucose Monitoring CRF Case Report Form Control-IQ System t:slim X2 insulin pump with Control-IQ technology DKA Diabetic Ketoacidosis eCRF Electronic Case Report Form EDC Electronic Data Capture FDA Food and Drug Administration GCP Good Clinical Practice HbA1c Hemoglobin A1c HCL Hybrid Closed-loop ICF Informed Consent Form QC Quality Control SAE Serious Adverse Event t:connect t:connect diabetes management system  T1D Type [ADDRESS_785524]  119 
  120 
Page B7
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  3 PROTOCOL SYNOPSIS  121 Protocol Title Initialization and Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes with AID Use Device 1) t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)  
2) An  automatic settings initializer and adaptation system running on the server Type of Study Prospective, Single Arm, Single Center Feasibility Study Rational The purpose of this study is to obtain preliminary safety and performance data on a settings initialization and adaptation 
algorithm used in conjunction with closed-loop control. Based on 
data from simulations and current system use, an algorithm to 
more accurately initialize settings and adapt them over time, faster 
than typi[INVESTIGATOR_595055], would benefit users onboarding from 
multiple daily injections ( MDI ) and help them reach optimal 
glycemic outcomes faster. Outcomes of this s tudy will allow for 
the determination of an optimal product configuration for adaptive 
settings and the ability to clinically test a commercial version of the new product for effectiveness. Objectives Primary objective: To demonstrate the safety of the system, by [CONTACT_595063] (needing 
assistance) compared to expected incidence  
 
Secondary objective : Compare time in range metrics and adverse 
events in the full 24 hour period, overnight and during the day, 
after each we ek of settings adaptation. The number of physician 
overrides/physician initiated changes in pump settings will also be tracked. Primary Endpoints 1) Primary Endpoint: a. To demonstrate the safety of the system, by [CONTACT_595064] s evere hypoglycemic events  (needing 
assistance)  compared to expected incidence  
2) Secondary Endpoints: 
a. Time in range 70-180 mg/dL 
b. Time < 54 mg/dL 
c. Time < 70 mg/dL 
d. Time > 180 mg/dL 
e. Time > 250 mg/dL 
f. Time in t ight glycemic range 70-140 mg/dL 
g. Post- prandial glycemic peak  
h. 4-hour post meal glucose AUC 
i. Sensor glucose median and interquartile range 
j. CGM metrics daytime vs. nighttime  
k. CGM metrics compared each week after adaptation  l. DKA Page B8
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  m. Adverse Device Effects n. Serious Adverse Events 
o. Change in total daily insulin use, basal and bolus 
p. Number of physician overrides/physician initiated 
changes in pump settings q. Patient Reported Outcomes Duration of Study Up to 17 weeks total, to allow for 2 to 4 weeks of CGM run-in if needed, then 13 weeks of pump/AID use with weekly settings adaptation Study Design $GXOWVDJHÂ•\HDUVRIDJHZLWKW\SHGLDEHWHVZKRDUHusing multiple daily injections, will be required to collect baseline CGM 
data for the first [ADDRESS_785525] 11 of 14 days of CGM use for the 14 days prior to 
enrollment.  They may repeat this 14 day run-in period if adequate 
CGM data is not collected, or study staff feel it is necessary to 
continue to monitor their insulin dose. 
 
Subjects will then proceed to pump/Control- IQ training , where an 
algorithm performed on a paper worksheet will be used to 
recommend initial basal rate , carbohydrate ratio and correction 
factor  settings .  
 
Subjects will then wear the insulin pump with Control- IQ 
technology active for 13 weeks, and at day 3 and at the end of 
each week will:  
1) Upload their pump using the USB uploader  
2) Have their study physician review the settings 
recommendations on the pump download report that will 
appear after each download.  
3) Change their settings after being called by [CONTACT_595065]. 
4) Upload their pump again so the study physician can verify 
the settings have been changed  appropriately , and verify 
the correct settings have been applied to the correct pump 
assigned to the subject by [CONTACT_595066] t:connect. 
5) Physicians can at any time adjust pump settings  and 
override the settings adaptation recommendations for 
safety concerns , and convert scheduled phone follow-up 
visits to in clinic visit at their discretion.  
 
A semi -structured one-on- one interview may be completed 
concurrent with the 13- Week Visit or within a [ADDRESS_785526] approximately 30 
minutes and will be conducted by [CONTACT_468513] a script of open-ended questions to gather feedback and reactions to the Page B9
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  automated initialization and adaptation system, as well as the use of Closed-Loop Control.  Study Population 0DOHDQGIHPDOHVXEMHFWVÂ•\HDUVRIDJHZLWKW\SHGLDEHWHVwho are current MDI users, who ha ve a baseline A1c at screening between 7.5 to 11% Number of Subjects Up to [ADDRESS_785527] 20 subjects complete the trial. Number of Sites 1 clinical site in the [LOCATION_002] Main Criteria for Inclusion Eligibility to enroll in the study will be assessed based on the following inclusion criteria:  
1. $GXOWVXEMHFWVÂ•DJH\HDUV  
2. Clinical diagnosis of type [ADDRESS_785528] one year  
3. Using a basal/bolus regimen by [CONTACT_17838] (MDI therapy) 
4. Total daily dose Â•10 units/day 
5. Willing to use only aspart (novolog) or lispro (humalog) 
U-100 insulin with the study pump.  
6. $FÂ•5DQGÂ”11% at screening  
7. Not pregnant or planning a pregnancy during the time 
period of the study. 
8. Has current glucagon product to treat severe hypoglycemia 
(injectable or nasal) at home (will provide prescription if 
they do not have one) 
9. Willingness to follow study procedures and a signed  informed consent form  Main Criteria for Exclusion Eligibility to enroll in the study will be assessed based on the following exclusion criteria:  
1. Two or more epi[INVESTIGATOR_116651] (needing 
assistance) in the past [ADDRESS_785529] 6 months  
4. History of drug abuse (defined as any illicit drug use) or 
history of alcohol abuse prior to screening or unwillingness 
to agree to abstain from illicit drugs throughout the study 
5. Significant chronic kidney disease or hemodialysis  
6. Significant liver disease  
7. History of adrenal insufficiency  
8. History of abnormal TSH consistent with hypothyroidism 
or hyperthyroidism that is not appropriately treated  
9. Other chronic disease/condition determined by [CONTACT_595067]  
10. Use of glucocorticoids, beta blockers or other medications determined by [CONTACT_595068] B10
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  11. Use of long-acting insulin, inhaled insulin (Afrezza), or use of any non-insulin glucose lowering agents (i.e. SGLT-2 
inhibitor) other than Metformin with the study pump  
12. Subject is pregnant or lactating or intending to become 
pregnant before or during participation in this study. 
13. Investigator judgement that subject would not be able to complete the trial. Procedures in Screening/Baseline 
Period  At screening, baseline data will be collected. For Decom G6 users, mean/median  sensor glucose, TIR and all glycemic outcomes will 
be recorded as baseline data if data is available for the at least [ADDRESS_785530] Dexcom G6 sensor data to establish a baseline over the next 2 weeks. Management of Adverse Events Safety information will be collected weekly during study clinic phone calls, or more frequently if a severe AE occurs. The event, 
date of onset, severity, seriousness, duration and relationship to the 
device /adaptation system  will be documented. All reported device-
related AEs will be followed until they are adequately resolved or 
stabilized, or until study completion/termination, whichever comes first. Statistical Analysis  Descriptive statistics will be used to evaluate rates of AEs as well as glycemic outcomes over time as the algorithm adapts insulin delivery settings.   122 
The study will be conducted and documented in accordance with the IRB, FDA, ICH and GCP 123 
guidelines. 124 
 125 
  126 
Page B11
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  4 BACKGROUND 127 
4.1 DISEASE BACKGROUND  128 
Type 1 diabetes affects 1.25 million people in the [LOCATION_002]. Approximately 70% of 129 
individuals with type 1 diabetes report poor metabolic control, and do not meet the American 130 
Diabetes Associationâ€™s recommended goal of hemoglobin A 1c (HbA 1c) level of 7.0% for children [ADDRESS_785531] that approximately 40 0,000 U.S. patients with type 1 diabetes (T1D) 134 
use insulin pumps. Adoption of pump therapy varies by [CONTACT_595069] 135 
healthcare provider preference or patient characteristics and socioeconomic status. Use of insulin 136 
pumps is more common in individuals of higher socioeconomic status as reflected by 137 
race/ethnicity, private health insurance, family income, and education. Additionally, referrals 138 
from healthcare providers and insurance approvals are c ritical determinants for who becomes a 139 
pump us er in the [LOCATION_002].  140 
However, a main barrier to starting pump therapy and staying on it is having to enter insulin 141 
delivery settings into the pump (ie basa l rate, carbohydrate ratio, correction factor) and [ADDRESS_785532] the safety and feasibility  of 143 
using a settings initializer for individuals onboarding to the t:slim X2 pump with Control- IQ 144 
technology, with weekly adaptations of insulin delivery settings over ~13 weeks.  145 
4.2 DEVICE BACKGROUND  146 
The t:slim X2 insulin pump with Control -IQ technology is an advanced hybrid closed-loop 147 
(HCL) system, developed and manufactured by [CONTACT_3438], Inc. and cleared in the 148 
U.S. by [CONTACT_3439] 1 diabetes. Control- IQ is integrated with the Dexcom 149 
G6 continuous glucose monitor (CGM) and uses CGM values to predict glucose values 30 150 
minutes in the future. Based on the predicted glucose, Control-IQ modulates basal insulin 151 
delivery, and delivers automated correction boluses to mitigate impending hyperglycemia. The 152 
current Control- IQ system is F DA approved down to age 6 years old for individuals with type 1 153 
diabetes, and has been found to improve time in range (70-180 mg/dL) and decrease both time < 154 
70 mg/dL and time >180 mg/dL (1,2). 155 
4.3 SETTINGS O PTIMIZER  156 
For this study, insulin delivery settings i nitialization will use a paper worksheet (Figure 1) to 157 
guide initial settings .  158 
 159 
 160 
Page B12
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  161 
Figure 1. Insulin pump initiation settings worksheet 162 
Adaptation will be recommended by [CONTACT_595070], emailing written recommendations 163 
for settings changes to physicians for their review. The automated settings adaptation system will 164 
recommend a single basal rate, carbohydrate ratio and correction factor throughout the day 165 
(Figure 2) , and will limit recommendations to a maximum 5% change at a time.  166 
Page B13
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61   167 
Figure 2.  Sample E -Mailed Adaptation Settings Recommendations 168 
If the user or study staff has manually changed settings to more than one timepoint per day, the 169 
settings adaptation system will continue to adapt back to one setting per day for basal rate, 170 
carbohydrate ratio and correction factor as shown in Figure 3. 171 
Page B14
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785533] report.  175 
Physician overrides of the system, or changes to pump settings between emailed 176 
recommendations, will be documented with the reason for the override/settings change on the 177 
study case report fo rm.  178 
179 
Page B15
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  5 STUDY OBJECTIVES, DESIGNS AND ENDPOINTS  180 
5.1 STUDY OBJECTIVES  181 
Primary objective : To demonstrate the safety of the settings initialization and adaptation 182 
algorithm when in conjunction with Control-IQ technology, by [CONTACT_595071] 183 
hypoglycemic events (needing assistance) compared to expected incidence  184 
Secondary objective: Compare time in range metrics and adverse events in the full 24 hour period, 185 
overnight and during the day, after each week of settings adaptation. The number of physician 186 
overrides/physician initiated changes in pump settings will also be tracked. 187 
5.2 STUDY DESIGN  188 
This feasibility study is a prospective, single arm study, evaluating an algorithm to recommend 189 
insulin pump settings at pump start (initialization) and then adjust settings at 3 days, at 7 days, 190 
and then weekly through 13 weeks. 191 
$GXOWVDJHÂ•\HDUVRIDJHZLWKW\SHGLDEHWHVZKRDUHXVLQJPXOWLSOHGDLO\LQMHFWLRQVZLOO[ADDRESS_785534] 20 subjects complete the trial.  198 
Enrollment goals for baseline A1c at screening are: 199 
â€¢ At least 5 subjects with A1c 8% - 8.9% 200 
â€¢ At least 5 subjects with A1c Â• 9% 201 
 202 
Subjects will then proceed to pump/Control-IQ training, where an algorithm based worksheet 203 
will be used to recommend initial basal rate , carbohydrate ratio and correction factor settings.  204 
Subjects will then wear the insulin pump with Control-IQ technology active, and at 3 days after 205 
training, 7 days after training, and then every 7 days will: 206 
1) Upload their pump using the USB uploader  207 
2) Have their study physician review the settings recommendations on the pump download 208 
report that will appear after each download. 209 
3) Change their settings after being called by [CONTACT_595072] 210 
recommendations. 211 
4) Upload their pump again so the study physician can verify the settings have been changed [ADDRESS_785535] settings changes were implemented  on the correctly 213 
assigned pump by [CONTACT_595073]. 214 
Page B16
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785536] pump settings and override the settings adaptation 215 
recommendations for safety concerns, and convert scheduled phone follow- up visits to in clinic 216 
visit at their discretion.  217 
After 13 weeks (3 months) of use, subjects will return to clinic for a final visit. [ADDRESS_785537] information will be offered an open ended interview 219 
at the end of the study to discuss their confidence in the automated settings recommendations 220 
and how it worked for them. 221 
The data collected in this study will be directly entered into the eCRF (as applicable) or paper [ADDRESS_785538] data will include demographics, focused medical history, therapy data, and 223 
baseline and follow-up measures. All device data will be collected digitally and downloaded 224 
directly into the manufacturer  provided software for the study devices. 225 
5.3 STUDY ENDPOINTS  226 
1) Primary Endpoint: 227 
a. To demonstrate the safety of the system, by [CONTACT_595074] s evere 228 
hypoglycemi c events  (needing assistance)  compared to expected incidence 229 
2) Secondary Endpoints: 230 
a. Time in range 70-180 mg/dL 231 
b. Time < 54 mg/dL 232 
c. Time < 70 mg/dL 233 
d. Time > 180 mg/dL 234 
e. Time > 250 mg/dL 235 
f. Time in tight glycemic range 70-140 mg/dL [ADDRESS_785539] meal glucose AUC 238 
i. Sensor glucose median and interquartile range 239 
j. CGM metrics daytime vs. nighttime  240 
k. CGM metrics compared each week after adaptation  241 
l. DKA  242 
m. Serious Adverse Events 243 
n. Adverse Device Effects  244 
o. Change in total daily insulin use, basal and bolus 245 
p. Number of physician overrides/physician initiated changes in pump settings  246 
q. Patient Reported Outcomes   247 
Page B17
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785540] POPULATION  249 
6.1.1  INCLUSION CRITERIA :  250 
Eligibility to enroll in the study will be assessed based on the following inclusion criteria:  251 
1) $GXOWVXEMHFWVÂ•DJH\HDUV  252 
2) Clinical diagnosis of type [ADDRESS_785541] one year  253 
3) Using a basal/bolus regimen by [CONTACT_17838] (MDI therapy) 254 
4) Total daily dos e Â•10 units/day 255 
5) Willing to use only aspart (novolog) or lispro (humalog) U-100 insulin with the study 256 
pump.  257 
6) $FÂ•5DQGÂ” 1% at screening  258 
7) Not pregnant or planning a pregnancy during the time period of the study. 259 
8) Has current glucagon product to treat severe hypoglycemia (injectable or nasal) at home 260 
(will provide prescription if they do not have one) 261 
9) Willingness to follow study procedures and a signed informed consent form  262 
6.1.2  EXCLUSION CRITERIA :  263 
Eligibility to enroll in the study will be assessed based on the following exclusion criteria:  264 
1) Two or more epi[INVESTIGATOR_116651] (needing assistance) in the past 6 months 265 
2) Two or more epi[INVESTIGATOR_595056] 6 months 266 
3) Inpatient psychiatric treatment in the past 6 months  267 
4) History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to 268 
screening or unwillingness to agree to abstain from illicit drugs throughout the study 269 
5) Significant chronic kidney disease or hemodialysis  270 
6) Significant liver disease  271 
7) History of adrenal insufficiency  272 
8) Hypothyroidism or hyperthyroidism that is not appropriately treated  273 
9) Other chronic disease/condition determined by [CONTACT_595075] 274 
in the study 275 
10) Use of glucocorticoids, beta blockers or other medications determined by [CONTACT_458486] 276 
interfere with study  277 
11) Use of long-acting insulin, inhaled insulin (Afrezza), or use of any non-insulin glucose 278 
lowering agents (i.e. SGLT-2 inhibitor) other than Metformin with the study pump 279 
12) Subject is pregnant or lactating or intending to become pregnant before or during 280 
participation in this study.  281 
13) Investigator judgement that subject would not be able to complete the trial. 282 
Page B18
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785542]â€™s [ADDRESS_785543] and will be included  in the analyses.  286 
 287 
288 
Page B19
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  7 TREATMENT OF SUBJECTS  289 
7.1 THE T:SLIM X2 INSULIN PUMP WITH CONTROL -IQ [ADDRESS_785544] insulin delivery with the goal of improving glucose 294 
control (time in range of 70-180 mg/dL).  295 
For the current study, subjects will use t:slim X2 pump with Control -IQ technology cleared 296 
under K201214 and K200467, respectively.  297 
7.2 ENROLLMENT PROCEDURE:  [ADDRESS_785545] will be asked to sign the informed consent form (ICF). 300 
Eligibility to enroll in the study will be assessed based on the inclusion/exclusion criteria.  301 
Enrollment information will be entered onto the study case report forms. In addition, 302 
demographic and relevant medical history will be collected at this time and entered onto the 303 
study case report forms.  304 
7.3 DURATION OF THERAPY AND FOLLOW -UP:  [ADDRESS_785546] may participate for ~1 7 weeks total, to allow for 2 to 4 weeks o f CGM 306 
run-in if needed, then 13 weeks of pump/AID use with weekly settings adaptation. 307 
7.4 STUDY PROCEDURES:  308 
Event Schedule: The CRFs will be completed by [CONTACT_093] (or an authorized member of 309 
the investigatorâ€™s staff) per the event schedule described below.  310 
  311 
Page B20
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  Table 1.  Schedule of Visits and Procedures 312 
 313 
Baseline Data Collection : $GXOWVDJHÂ•\HDUVRIDJHZLWKW\SHGLDEHWHVZKRDUHXVLQJ [ADDRESS_785547] Completion or Early Withdrawal: The subject completes the study approximately 17- 318 
21 weeks after enrollment, or when they choose to withdraw from the study, if earlier than the 319 
final visit  320 
Data Collection:  Investigators will assign a de -identified number to each subject and will be 321 
required to keep any study paperwork or electronic files in a secure private area. Monitoring will 322 
be conducted to help ensure that data is secure and entered within reasonable li mits, consistent 323 
with a risk -based monitoring approach. 324  Screening 
Visit  CGM  
Run-in Visit  
(may be 
repeated 
after 2 
weeks)  Pump and 
Control -IQ 
Training 
Visit  Control -IQ Use  
  2-4 weeks   3d 7d Weekly  13w F/U Call UV 
Visit (V) or Contact (C)  V V V C C C V C C/V 
Informed Consent  X         
Eligibility Assessment  X         
Medical history/  
physical exam  X         
Vital Signs  X         
HbAlc (POC or local lab for 
inclusion criteria 
confirmation)  X         
HbA1c (Central lab)     X    X   
Pregnancy test  (females 
of child -bearing potential)  X  X       
Assessment of CGM use  X X        
Study system training   X X       
AE Assessment   X X X X X X X X 
Upload device data 
from home     X X X   X 
Download  device data 
at clinic visit  X X X    X  X 
Open Ended Interview        X   
Page B21
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  Demographics:  The following demographic data will be obtained: date of birth, gender, race, 325 
ethnicity, educational level, socioeconomic status, residence, employment status, weight, height, 326 
blood pressure, pulse, and type of health insurance.   327 
Medical History:  Medical history, including existing comorbidities deemed clinically relevant 328 
(e.g. retinopathy, nephropathy, neuropathy, history of cardiovascular events) will be collected at [ADDRESS_785548]â€™s eCRF.  A new hemoglobin A1c will also be obtained at the screening visit , at 332 
randomization and at end of study. 333 
Pregnancy: In order to reduce the risk of pregnancy, subjects of childbearing potential must [ADDRESS_785549].  337 
Device Training:  All subjects will complete study device training before starting use of the [ADDRESS_785550] scheduled phone follow up visits at 3 days (+/- 1 day), 7 days (+/- 2 days), then weekly 351 
(+/- 3 days). A final visit in clinic will occur at 13 weeks (+/ - 7 days). A post final clinic visit  352 
phone call will occur 3 days (+/ - 1 day) after changing back to MDI therapy after the study [ADDRESS_785551]. 359 
At any time, study staff providers may override the algorithm settings recommendations, either 360 
at or in between scheduled visits for safety concerns. The reason for any changes to override 361 
pump settings will be documented.  362 Page B22
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785552] approximately 30 minutes and 366 
will be conducted by [CONTACT_468513] a script of open-ended questions to gather feedback and 367 
reactions to the automated initialization and adaptation system, as well as the use of Closed -Loop 368 
Control. 369 
Interview sessions may be audio- or video-taped and transcribed by a professional transcription 370 
service. Otherwise, these recordings will not be shared for any non-study purposes. 371 
Transcriptions will use a code for participants, such as â€œParticipant 1â€, and will not contain 372 
names or other identifiers of participants. 373 
Observation and Recording of Adverse Events: Subjects will be required to report AEs. Open- [ADDRESS_785553] be recorded in source 377 
documentation and on the appropriate eCRF using medical terminology. 378 
Treatment of hyper - and hypoglycemia: Procedures in Section 10.9 and 10.10  will be 379 
followed by [CONTACT_595076]. 380 
7.5 EARLY TERMINATION VISIT (IF APPLICABLE)  [ADDRESS_785554] 386 
insulin delivery settings on the study pump at any time, and override the algorithm 387 
recommendations for safety concerns, and will document these changes. 388 
7.7 FINAL CLINIC  VISIT  389 
Subjects wi ll return all study supplies and complete the study surveys.  390 
A final central lab HbA1c will be drawn.  391 
All study devices (glucose meter, ketone meter, insulin pump and CGM) will be downloaded.  [ADDRESS_785555] and Device Satisfaction (DIDS) Scale , and be asked [ADDRESS_785556] information for a final interview phone call. 397 Page B23
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785557]â€™s baseline therapy doses, noting changes in basal [ADDRESS_785558] match the current daily insulin requirements from CSII 401 
use, typi[INVESTIGATOR_897] = (total daily dose + 20%)/2, with further modification as per clinical site [ADDRESS_785559] -study phone call 3 (Â±1) days after the date of their final visit and 410 
transition back to their prior insulin therapy, during which the following will occur:  411 
x Check on transition back to usual home diabetes care 412 
x Assessment of adverse events 413 
  414 
Page B24
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  8 STATISTICAL CONSIDERATIONS   415 
8.1 STATISTICAL ANALYSIS:  416 
This feasibility study is a prospective, single arm study, evaluating al algorithm to recommend 417 
insulin pump settings at pump start (initialization) and then weekly for 13 weeks. 418 
Descriptive statistics of the rates of severe hypoglycemia, DKA, and serious adverse events will 419 
be reported for baseline (with CGM run -in data) and compared to changes after each weekly 420 
adap tation. Additionally, descriptive statistics of glycemic outcomes will for baseline and each 421 
intervention configuration will be provided.  422 
The statistics will include  all primary and secondary outcomes of the study as listed in section 423 
5.3. These statistics will be calculated at the patient -level, and a sub-analysis of daytime vs. 424 
nighttime statistics will be provided.  425 
 426 
  427 
Page B25
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  9 RISKS AND BENEFITS  428 
9.1 POTENTIAL RISKS AND BENEFITS OF THE DEVICE  429 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data 430 
are handled to minimize this risk. Hypoglycemia, hyp erglycemia and ketone formation are 431 
always a risk in participants with diabetes  and participants will be monitored for this. 432 
9.2 VENIPUNCTURE RISKS  433 
A hollow needle/plastic tube may be placed in the arm for taking blood samples . Blood draws 434 
can cause some commo n reactions like pain, bruising, or redness at the sampling site. Less 435 
common reactions include bleeding from the sampling site, formation of a small blood clot or 436 
swelling of the vein and surrounding tissues, and fainting. 437 
9.3 FINGERSTICK RISKS  438 
About 1 drop of blood will be removed by [CONTACT_595077] 439 
sometimes Hemoglobin A1c ( HbA1c ) or other tests. This is a standard method used to obtain [ADDRESS_785560] for several weeks. The risk of local infection is less than 1 in 1000. This should not be a 443 
significant contributor to risks in this study as fingerstick s are part of the usual care for people 444 
with diabetes.  445 
9.4 SUBCUTANEOUS CATHETER RISKS (CGM)  446 
With CGM use participants are at low risk for developi[INVESTIGATOR_007] a local skin infection at the site of the 447 
sensor needle placement. If a catheter is left under the skin for more than 24 hours, it is possible 448 
to get an infection where it goes into the skin, with swelling, redness and pain. There may be 449 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk). [ADDRESS_785561] a small portion of the sensor probe under the 451 
skin that may cause redness, swelling or pain at the insertion site. The participant will be 452 
instructed to notify the study coordinator immediately if this occurs. 453 
9.5 RISK OF HYPOGLYCEMIA  454 
As with any person having diabetes  and using insulin, there is always a risk of having a low 455 
blood sugar (hypoglycemia). The frequency of hypoglycemia should be no more and possibly [ADDRESS_785562] as at home, there is the possibility of fainting or seizures 458 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 459 
hypoglycemia. A CGM functioning poorly and significantly over-reading glucose values could 460 
lead to inappropriate insulin delivery. 461 
Page B26
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785563] strips, and a ketone 466 
meter and ketone strips to use to carefully monitor for hyperglycemia and be given instructions 467 
on how to mitigate hyperglycemia should it occur. 468 
9.7 RISK OF DEVICE REUSE  469 
All devices will be used by a single study participant only. There will be no device re- use. 470 
9.8 OTHER RISKS  471 
Some par ticipants may develop skin irritation or allergic reactions to the adhesives used to secure 472 
the CGM, or from tape to secure the insulin infusion sets for the continuous subcutaneous insulin 473 
infusion.  If these reactions occur, different adhesives or â€œunder-tapi[INVESTIGATOR_007]â€ (such as with IV 3000, 474 
Tegaderm, etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_3406] 475 
other medication may be required.  476 
Whenever the skin is broken there is the possibility of an infection. The CGM and pump infusion 477 
sites are inserted under the skin. It is possible that any part that is inserted under the skin may 478 
cause an infection. These occur very infrequently, but, if an infection was to occur, oral and/or [ADDRESS_785564]â€™s home pump will include data from prior to the date of the screening visit. 485 
Some people may  be uncomfortable with the researchers' having such detailed information about 486 
their daily diabetes habits. 487 
9.9 KNOWN POTENTIAL BENEFITS  488 
Participants may experience a significant improvement in glucose control. Hypoglycemia is the 489 
number one fear of many individuals taking insulin and this fear often prevents o ptimal glycemic 490 
control. Hyperglycemia will likely be reduced as well.  491 
It is expected that this protocol will yield increased knowledge about using an automated 492 
closed -loop to control glucose levels in people with type 1 diabetes. The individual participant 493 
may or may not benefit from study participation. 494 
9.10 RISK ASSESSMENT  495 
Based on the facts that (1) adults and adolescents with type 1 diabetes experience mild 496 
hypoglycemia and hyperglycemia frequently as a consequence of the disease and its 497 
management, (2) th e study intervention involves periodic automated insulin dosing that may 498 Page B27
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  increase the likelihood of hypoglycemia, and periodic automated attenuation of insulin delivery 499 
that may increase the likelihood of hyperglycemia, (3) mitigations are in place, and have been 500 
tested in prior studies using the investigational device system in the home setting, that limit the 501 
likelihood of excessive insulin dosing or prolonged withdrawal of insulin, (4) rapid reversal of 502 
hypoglycemia and hyperglycemia can be achieved, and (5) the Control algorithm (Control- IQ) is 503 
already FDA approved for and has shown significant (10+%) TIR improvements in individuals [ADDRESS_785565] their origin in the Declaration of Helsinki, with 511 
the protocol described herein, and with the standards of Good Clinical Practice (GCP). 512 
  513 
Page B28
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  10 DESCRIP TION OF THE STUDY DEVICES AND USE  514 
All study supplies will be provided by [CONTACT_3438], Inc. 515 
10.1 INSULIN PUMP  516 
The study system will include the Tandem t:slim X2 insulin pump with Control-IQ technology 517 
cleared under K201214 and K200467 respectively ( Tandem Diabetes Care, San Diego, CA). [ADDRESS_785566] once every 10 days or as per manufacturer instructions.  521 
10.3 BLOOD GLUCOSE METER AND STRIPS  522 
Blood glucose levels will be measured using the study-assigned blood glucose meter 523 
(glucometer) and the CGM device will be calibrated if needed using the study glucometer 524 
and strips in accordance with the manufacturerâ€™s labeling.  (Contour NEXT or Contour NEX T [ADDRESS_785567], Parsippany, NJ [ZIP_CODE] [LOCATION_003]) 526 
10.4 KETONE METER AND STRIPS  527 
Blood ketone levels will be measured using the Abbott Precision Xtra meter and strips in 528 
accordance with the manufacturerâ€™s labeling. The blood glucose meter component of the 529 
Precision Xtra device will not be used. (Abbott Diabetes Care Inc., [ADDRESS_785568], 530 
Alameda, CA [ZIP_CODE] [LOCATION_003]) [ADDRESS_785569]â€™s study chart, to include [ADDRESS_785570]. Additional 537 
QC testing may be performed per manufacturer guidelines. 538 
x A tested meter will not be used in a study if it does not read within the target range 539 
concentration per manufacturer labeling.  540 
x Participants will be reminded t o use the study blood glucose meter for all fingerstick blood 541 
glucose measurements.  542 
x Participants will be asked to perform fingerstick blood glucose measurements in accordance 543 
with the labelling of the study CGM device. 544 
Page B29
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785571]. Additional 546 
QC testing may be performed per manufacturer guidelines. 547 
x A tested meter will not be used in a study if it does not read within the target range 548 
concentration per manufacturer label ing.  549 
x Participants will be instructed on how to perform blood ketone testing. 550 
x Participants will be given guidelines for treatment of elevated blood ketones. 551 
10.8 CGM CALIBRATION  552 
Throughout the study, participants will be instructed to calibrate the study CGM in accordance 553 
with manufacturer labelling. 554 
10.9 HYPERGLYCEMIA SAFETY PROTOCOL  555 
The t:slim X2 with Control -IQ system will issue a predictive hyperglycemia alert (Control -IQ 556 
High Alert) when the system has increased insulin delivery, but detects a CGM value above 200 557 
mg/dL and does not predict the value will decrease in the next 30 minutes. During the course of 558 
the study, participants will be permitted to change the CGM high glucose threshold alert setting 559 
on their device or mobile app, but will be instructed to choose a value no greater than 300 560 
mg/dL. [ADDRESS_785572] blood glucose. 563 
If a participantâ€™s CGM reading is >300 mg/dL for more than 60 minutes RULVÂ•PJG/DWDQ\ 564 
point, the participant will be instructed to take the following steps: 565 
x Perform a blood glucose meter check. 566 
x If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter. 567 
x ,IWKHNHWRQHOHYHOLVÂ•PPRO/  RUÂ•PPRO \L at any time), take correction insulin, 568 
change insulin (pump) infusion site and contact [CONTACT_464]. Continue to monitor their glucose 569 
and blood ketone levels until they return to normoglycemia and ketones are < 0.6 mmol/l. 570 
x If ketones are <0.6 mmol/l, they will be advised to continue to monitor their glucose until it 571 
returns to normoglycemia and to repeat the ketone measurement in 90 minutes if necessary  572 
x If correction insulin is administered via insulin syringe, turn Control- IQ off for four  hours 573 
and until glucose level has returned to <180 mg/dL. 574 
10.10  HYP OGLYCEMIA SAFETY PROTOCOL  575 
When using the study device, hypoglycemia low threshold alerts will be set to no lower than 70 576 
mg/dL, and if a participantâ€™s CGM reading is <70 mg/dL, subjects will be instructed to treat with 577 
~15 grams of carbohydrate, and perform fingerstick testing as necessary per CGM manufacturer 578 
instructions. 579 Page B30
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  11 ADVERSE EVENTS, DEVICE ISSUES, AND STOPPI[INVESTIGATOR_1645] 580 
RULES 581 
11.1 ADVERSE EVENTS  582 
Adverse Event (AE):  Any untoward medical occurrence in a  study participant, irrespective of the 583 
relationship between the adverse event and the device(s) under investigation (see section 11.2 for 584 
reportable adverse events for this protocol). 585 
Serious Adverse Event (SAE): Any untoward medical occurrence that: 586 
Results in death. 587 
Is life -threatening; (a non- life-threatening event which, had it been more severe, might have 588 
become life -threatening, is not necessarily considered a serious adverse event). 589 
Requires inpatient hospi[INVESTIGATOR_1081]. 590 
Results in persistent or significant disability/incapacity or substantial disruption of the ability to [ADDRESS_785573] normal life functions (sight threatening). [ADDRESS_785574]. 593 
Is considered a significant medical event by [CONTACT_13656] (e.g., 594 
may jeopardize the participant or may require medical/surgical intervention to prevent one of the 595 
outcomes listed above).  [ADDRESS_785575] (UADE):  Any serious adverse effect on health or safety or [ADDRESS_785576], 598 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 599 
investigati onal plan or application (including a supplementary plan or application), or any other 600 
unanticipated serious problem associated with a device that relates to the rights, safety, or 601 
welfare of participants (21 CFR 812.3(s)). [ADDRESS_785577] (ADE):  Any untoward medical occurrence in a study participant which [ADDRESS_785578] contributed (Note that an Adverse 604 
Event Form is to be completed in addition to a Device Deficiency or Issue Form). 605 
Device Complaints and Malfunctions: A device complication or complaint is something that 606 
happens to a device or related to device performance, whereas an adverse event happens to a 607 
participant. A device complaint may occur independently from an AE, or along with an AE. 608 
An AE may occur without a device complaint or there may be an AE related to a device 609 
complaint. A device malfunction is any failure of a device to meet its performance specifications 610 
or otherwise perform as intended. Performance specifications include all claims made in the 611 
labeling for the device. The intended performance of a device refers to the intended use for 612 
which the device is labeled or marketed. (21 CFR 803.3). Note: for reporting purposes, sites 613 
will not be asked to distinguish between device complaints and malfunctions. 614 
Page B31
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785579] medical occurrence that 616 
meets one of the following criteria:  [ADDRESS_785580] as defined in section  11.1, unless excluded from reporting in 619 
section 11.9 620 
3. An Adverse Event occurring in association with a study procedure 621 
4. Hypoglycemia meeting the definition of severe hypoglycemia as defined below  622 
5. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, a [ADDRESS_785581]. Skin reactions from sensor placement 626 
are only reportable if severe and/or required treatment.  [ADDRESS_785582] is only reportable as an adverse 630 
event when the following definition for severe hypoglycemia is met: the event required [ADDRESS_785583] ance of another person due to altered consciousness, and required another person to actively 632 
administer carbohydrate, glucagon, or other resuscitative actions. This means that the participant 633 
was impaired cognitively to the point that he/she was unable to treat himself/herself, was unable 634 
to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure 635 
or coma. These epi[INVESTIGATOR_418080] 636 
coma. If plasma glucose meas urements are not available during such an event, neurological 637 
recovery attributable to the restoration of plasma glucose to normal is considered sufficient 638 
evidence that the event was induced by a low plasma glucose concentration. 639 
11.4 HYPERGLYCEMIC EVENTS/DIABETIC KETOACIDOSIS  [ADDRESS_785584] is only reportable as an adverse 641 
event when one of the following 4 criteria is met:  642 
the event involved DKA, as defined by [CONTACT_3467] 643 
(DCCT) and described below 644 
evaluation or treatment was obtained at a health care provider facility for an acute event 645 
involving hyperglycemia or ketosis 646 
EORRGNHWRQHOHYHOÂ• 0.6 mmol/L and communication occurred with a health care provid er at 647 
the time of the event  648 
Page B32
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  EORRGNHWRQHOHYHOÂ• 2.5 mmol/L, even if there was no communication with a health care 649 
provider 650 
Hyperglycemic events are classified as DKA if the following are present:  651 
Symptoms such as polyuria, polydipsia, nausea, or vomiting; 652 
Serum ketones >1.5 mmol/L or large/moderate urine ketones; 653 
Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and 654 
Treatment provided in a health care facility  655 
All reportable Adverse Events â€”whether volunteered by [CONTACT_2299], discovered by [CONTACT_3449] [ADDRESS_785585], or other 657 
means â€”will be reported on an adverse event form online. Each adverse event form is reviewed [ADDRESS_785586] be en caused 662 
by [CONTACT_19911]. 663 
To ensure consistency of adverse event causality assessments, investigators should apply the 664 
following general guideline when determining whether an adverse event is related: 665 
Yes 666 
There is a plausible temporal relationship between the onset of the adverse event and the study 667 
intervention, and the adverse event cannot be readily explained by [CONTACT_2299]â€™s clinical state, 668 
intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the adverse event follows a known pattern 669 
of respo nse to the study intervention; and/or the adverse event abates or resolves upon 670 
discontinuation of the study intervention or dose reduction and, if applicable, reappears upon 671 
re-challenge.  672 
No 673 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., 674 
preexisting medical condition, underlying disease, intercurrent illness, or concomitant 675 
medication); and/or the adverse event has no plausible temporal relationship to study 676 
intervention. 677 
11.6 INTENSITY OF ADVERSE EVENT  678 
The inten sity of an adverse event will be rated on a three point scale: (1) mild, (2) moderate, or 679 
(3) severe. It is emphasized that the term severe is a measure of intensity: thus a severe adverse 680 
event is not necessarily serious. For example, itching for several days may be rated as severe, but 681 
may not be clinically serious. 682 Page B33
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  MILD: Usually transient, requires no special treatment, and does not interfere with the participantâ€™s 683 
daily activities.  684 
MODERATE: Usually causes a low level of inconvenience or concern to the participant and may interfere 685 
with daily activities, but is usually ameliorated by [CONTACT_14212].  686 
SEVERE: Interrupts a participantâ€™s usual daily activities and generally requires systemic drug therapy or 687 
other treatment.  688 
11.7 CODING OF ADVERSE EVENTS  689 
Adverse events will be coded using the MedDRA dictionary. T he investigatorâ€™s assessment will 690 
be recorded.  691 
Adverse events that continue after the participantâ€™s discontinuation or completion of the study 692 
will be followed until their medical o utcome is determined or until no further change in the 693 
condition is expected. 694 
11.8 OUTCOME OF ADVERSE EVENT  695 
The outcome of each reportable adverse event will be classified by [CONTACT_3470]: 696 
RECOVERED/RESOLVED â€“ The participant recovered from the AE/SAE without sequelae. [ADDRESS_785587] the AE/SAE stop date.  698 
RECOVERED/RESOLVED WITH SEQUELAE â€“ The event persisted and had stabilized [ADDRESS_785588] the AE/SAE stop date. 700 
FATAL â€“ A fatal outcome is defined as the SAE that resulted  in death. Only the event that was 701 
the cause of death should be reported as fatal. AEs/SAEs that were ongoing at the time of death; 702 
however, were not the cause of death, will be recorded as â€œresolvedâ€ at the time of death.  703 
NOT RECOVERED/NOT RESOLVED (ONGOING) â€“ An ongoing AE/SAE is defined as the 704 
event was ongoing with an undetermined outcome. 705 
An ongoing outcome will require follow-up by [CONTACT_595078] 706 
the AE/SAE.  707 
The outcome of an ongoing event at the time of death that was not the cause of death, will be 708 
updated and recorded as â€œresolvedâ€ with the date of death recorded as the stop date.  709 
UNKNOWN â€“ An unknown outcome is defined as an inability to access the participant or the 710 
participantâ€™s records to determine the outcom e (for example, a participant that was lost to follow - 711 
up). 712 
All clinically significant abnormalities of clinical laboratory measurements or adverse events  713 
occurring during the study and continuing at study termination should be followed by [CONTACT_941] 714 
participantâ€™s  physician and evaluated with additional tests (if necessary) until diagnosis of the 715 
underlying cause, or resolution. Follow-up information should be recorded on source documents. 716 
Page B34
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785589] the participant until the adverse event has resolved or stabilized.  721 
11.9 REPORTABLE DEVICE ISSUES  722 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 723 
whether an adverse event occurred, except in the following circumstances.  724 
The following device issues are anticipated and will not be reported on a Device Issue Form but 725 
will reported as an Adverse Event if the criteria for AE reporting described above are met:  726 
1) Component disconnections 727 
2) CGM sensors lasting fewer than the number of days expected per CGM labeling 728 
3) CGM tape adherence issues  729 
4) Pump infusion set occlusion not leading to ketosis 730 
5) Battery lifespan deficiency due to inadequate charging or extensive wireless 731 
communic ation  732 
6) Intermittent device component disconnections/communication failures not leading to 733 
system replacement  734 
7) Device issues clearly addressed in the user guide manual that do not require additional 735 
troubleshooting 736 
8) Skin reactions from CGM sensor placement or pump infusion set placement that do not [ADDRESS_785590] be recorded within 24 hours via completion of the serious adverse event 743 
form and sponsor notification. 744 
Other reportable adverse events, device malfunctions (with or without an adverse event), and [ADDRESS_785591] or Ethics 749 
Committee.  750 
Upon receipt of a UADE report, the study principal investigators will investigate the UADE and 751 
if indicated, report the results of the investigation to the sitesâ€™ IRBs, and the Sponsor (Tandem 752 
Diabetes Care) within ten working days of becoming aware of the UADE per 21CFR 812.46(b) 753 Page B35
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  (2). The Sponsor must determine if the UADE presents an unreasonable risk to participants. If [ADDRESS_785592] receipt notice of the UADE.  757 
In the case of a device system component malfunction (e.g. pump, CGM, control algorithm), 758 
information will be forwarded to the responsible company by [CONTACT_14523], to be handled 759 
by [CONTACT_212414].  760 
11.12  PARTICIPANT DISCONTINUATION OF STUDY DEVICE  761 
Rules for discontinuing study device use are described belo w. 762 
1) The investigator believes it is unsafe for the participant to continue on the intervention. 763 
This could be due to the development of a new medical condition or worsening of an 764 
existing condition; or participant behavior contrary to the indications for use of the 765 
device that imposes on the participantâ€™s safety  766 
2) The participant requests that the treatment be stopped  767 
3) Participant pregnancy  768 
If pregnancy occurs, the participant will be discontinued from the study entirely. 769 
Otherwise, even if th e study device system is discontinued, the participant will be 770 
encouraged to remain in the study through the final study visit. 771 
4) Two distinct epi[INVESTIGATOR_590481] 11.4 772 
5) Two distinct epi[INVESTIGATOR_595057] 11.3 773 
6) The investigator may have a subject temporarily stop use of Control-IQ during: periods 774 
of significant illness,  temperature >101. 5, use of oral or injectable glucocorticoids , use of [ADDRESS_785593] from the study. 779 
11.13  CRITERIA FOR SUSPENDING OR STOPPI [INVESTIGATOR_595058] 780 
STUDY  781 
1) In the case of a system malfunction resulting in a severe hypoglycemia or severe 782 
hyperglycemia event (as defined in section s 11.3 and 11.4), use of the study device 783 
system will be suspended while the problem is diagnosed. 784 
2) Three or more cases of severe hypoglycemia or three or more cases of severe 785 
hyperglycemia (as defined in section s 11.3 and 11.4) across the entire study.  786 
3) In addition, study activities could be similarly suspended if the manufacturer of any 787 
constituent study device requires stoppage of device use for safety reasons (e.g. product 788 
recall). The affected study activities may resume if the underlying problem can be 789 
corrected by a protocol or system modification that will not invalidate the results 790 
obtained prior to suspension. 791 Page B36
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  The Sponsor (Tandem Diabetes Care) will be informed of all serious adver se events and [ADDRESS_785594] suspension of study 794 
activities or stoppage of the study if deemed necessary based on the totality of safety data 795 
available.  796 
11.14  SAFETY OVERSIGHT  797 
The clinical site principal investigator [INVESTIGATOR_595059] 798 
effects, and report them to the study sponsor. 799 
As this is a single site clinical feasibility study, the Medical Director from the study sponsor will 800 
carefully review all adverse event reports , and adjudicate their relationship the study device 801 
based on the site principal investigatorâ€™s report and all available information . 802 
 803 
  804 
Page B37
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785595] their personal 812 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the 813 
trial. 814 
Treatment with any non-insulin glucose-lowering agent other than metformin (including GLP-1 815 
agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas and naturaceuticals) or 816 
Afrezza  will not be permitted during the trial.  817 
The investigational study devices (study insulin pump, study phone, study CGM systems) must 818 
be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) or 819 
diathermy treatment. Participants may conti nue in the trial after temporarily discontinuing use if 820 
requiring one of the treatments above. 821 
12.3 PARTICIPANT COMPENSATION  822 
Participant compensation will be specified in the informed consent form. 823 
12.1 PARTICIPANT ACCESS TO STUDY DEVICE AT STUDY 824 
CLOSURE 825 
Participant  will return all study devices and supplies (insulin pump, CGM and related supplies) 826 
at study closure. Participant may keep the study ketone meter and study glucometer if these 827 
devices are not marked for investigational use only. 828 
 829 
  830 
Page B38
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  13 DATA COLLECTION AND MON ITORING  831 
13.1 CASE REPORT FORMS AND DEVICE DATA  832 
The main study data are collected through a combination of paper /electronic  case report forms 833 
(CRFs)  and electronic device data files obtained from the study software and individual [ADDRESS_785596] ronic device files and paper /electronic  CRFs  are considered [ADDRESS_785597]. These documents should 847 
be retained for a longer period, however, if required by [CONTACT_427]. No records will be 848 
destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the 849 
sponsor to inform the investigator when these documents no longer need to be retained. 850 
13.3 PROTOCOL DEVIATI ONS  851 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 852 
requirements. The noncompliance may be either on the part of the participant, the investigator, or 853 
the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_779] 854 
and implemented promptly. The site PI/study staff is responsible for knowing and adhering to [ADDRESS_785598]  857 
The investigator will ensure that this study is conducted in full conformity with Regulations for 858 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 859 
21 CFR Part 56, and/or the ICH E6. 860 
13.5 INSTITUTIONAL REVIEW BOARDS  861 
The protocol, informed consent form(s), recruitment materials, and all parti cipant materials will [ADDRESS_785599] be obtained before any participant is enrolled. Any amendment to the protocol will 864 
require review and approval by [CONTACT_3484]. All 865 
changes to the consent form will be IRB approved; a determination will be made regarding 866 
whether previously consented participants need to be re-consented. 867 Page B39
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from 21 CFR 20.61  13.6 CONSENT PROCEDURES AND DOCUMENTATION  868 
Informed consent is a process that is initiated prior to the individualâ€™s agreeing to participate in 869 
the study and continues throughout the individualâ€™s study participation. Extensive discussion of [ADDRESS_785600] the opportunity to discuss the study with their surrogates or think 878 
about it prior to agreeing to participate. The participant will sign the informed consent document 879 
prior t o any procedures being done specifically for the study. The participants may withdraw 880 
consent at any time throughout the course of the trial. A copy of the informed consent document 881 
will be given to the participants for their records. The rights and welfar e of the participants will 882 
be protected by [CONTACT_595079] 883 
affected if they decline to participate in this study.  884 
13.7 PARTICIPANT AND DATA CONFIDENTIALITY  885 
The study monitor, other authorized representatives of the sponsor, such as the study 886 
coordinating center, representatives of the IRB or authorized representatives from the clinical 887 
site(s) or Tandem Diabetes Care, Inc., may inspect all documents and records required to be 888 
maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or 889 
hospi[INVESTIGATOR_307]) for the participants in this study. The clinical study sites will permit access to such 890 
records.  891 
The study participantâ€™s contact [CONTACT_595080] 892 
internal use during the study. At the end of the study, all records will continue to be kept in a 893 
secure location for as long a period as dictated by [CONTACT_46202]. 894 
Study participant research data, which is fo r purposes of statistical analysis and scientific 895 
reporting, will be transmitted from the clinical site(s) and sent to Tandem Diabetes Care. This 896 
will not include the participantâ€™s contact [CONTACT_1290]. Rather, individual [ADDRESS_785601] protected. At the end of the study, all study databases will be de- identif ied and 900 
archived at the clinical site(s). Permission to transmit data will be included in the informed [ADDRESS_785602] of 1996 (HIPAA). In addition, all personal data will be handled in 904 
accordance with the EU directive e95/46/EC and as of 25 May 2018 in accordance with the 905 
GDPR. All data will be de -identified at each site before being entered into the case report forms . 906 
Page B40
   Confidential     
   Contains trade secrets and/or confidential information exempt fr om disclosure from [ADDRESS_785603] know: 908 
x What protected health information (PHI) will be collected during the study; [ADDRESS_785604] access to that information; 910 
x Who will use or disclose that information;  [ADDRESS_785605] to revoke their authorization for use of their PHI. 912 
 913 
13.8 PARTICIPANT WITHDRAWAL  914 
Participation in the study is voluntary, and a participant may withdraw at any time. 915 
For participants who withdraw, t heir data will be used up until the time of withdrawal.  916 
13.9 CONFIDENTIALITY  917 
For security and confidentiality purposes, participants will be assigned an identifier that will 918 
be used instead of their name. Protected health information gathered for this study will be 919 
VHFXUHO\VWRUHGDWWKHFOLQLFDOVLWH'Há€©LGHQWLILHGSDUWLFLSDQWLQIRUPDWLRQPD\DOVREHSURYLGHGWR920 
the Sponsor consistent with these guideline s. 921 
Page B41
 
41 
 14 REFERENCES 
1. Brown SA, Kovatchev BP, Raghinaru D, Lum JW et al. Six-month randomized, 
multicenter trial of closed -loop control in type 1 diabetes. N Engl J Med . 2019; 
381(18):1707-1717.  
2. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L et al. A randomized trial of closed-
loop control in children with type 1 diabetes. N Engl J Med . 2020; 383(9):836-845.  
 
 
 
Page B42